Showing results (1-10 of 174) with videos related to
Sort By:
Pageof 18
DNA and Cell Biology|May 31, 2024
MERTK and Fibrosis: A New Target for TherapyZiyan Pan, Mohammed EslamCurrent Opinion in Pharmacology|August 29, 2021
An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunitiesZiyan Pan, Jian-Gao Fan, Mohammed EslamHepatology International|August 28, 2024
Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLDMingqian Jiang, Ziyan Pan, Jacob George, et al.Frontiers in Bioscience (Landmark Edition)|April 29, 2024
A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune CellsZiyan Pan, Jawaher Alharthi, Ali Bayoumi, et al.Plos One|May 9, 2024
Exportin 4 DNA promoter methylation in liver fibrosisZiyan Pan, Ali Bayoumi, Mayada Metwally, et al.Hepatology International|June 20, 2024
Telomere length and mortality in lean MAFLD: the other face of metabolic adaptationMohammad Alarabi, Ziyan Pan, Manuel Romero-Gómez, et al.Liver International : Official Journal of the International Association for the Study of the Liver|April 20, 2024
MAFLD predicts cardiovascular disease risk better than MASLDZiyan Pan, Gamal Shiha, Gamal Esmat, et al.European Journal of Gastroenterology & Hepatology|January 19, 2026
Metabolic dysfunction-associated fatty liver disease increases the risk of sleep abnormalities: an analysis of the National Health and Nutrition Examination Survey 2017-2020Alaa M Mostafa, Yasser Fouad, Mohamed AbdAllah, et al.Drug Design, Development and Therapy|March 2, 2026
Beyond Organ-Specific Therapies: A Unified Approach to Multi-Organ FibrosisZiyan Pan, Shadi Zerehpoosh, Shu-Chi Wang, et al.Annals of Hepatology|May 6, 2024
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney diseaseZiyan Pan, Moutaz Derbala, Khalid AlNaamani, et al.Pageof 18